Drugs / SY-9453
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07469982 | Mar 2026 → Feb 2027 expected | SMARCA4-deficient sarcoma of thorax | Shouyao Holdings (Beijing) Co. LTD | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SY-9453 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07469982 ↗ |
| Route | Oral | “for oral administration” NCT07469982 ↗ |